Examining the first triple incretin agonist peptide targeting GLP-1, GIP, and glucagon receptors simultaneously.
Retatrutide (LY3437943) is a novel 39-amino-acid peptide developed by Eli Lilly that functions as a triple agonist, simultaneously targeting the glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon receptors. This triple receptor engagement distinguishes Retatrutide from earlier incretin-based peptides such as semaglutide, which acts on GLP-1 receptors alone, and tirzepatide, which targets both GLP-1 and GIP receptors. By engaging all three metabolic receptors in a single molecule, Retatrutide represents a new class of multi-receptor agonist peptides for advanced metabolic research.
With a molecular weight of approximately 4,500 Da, Retatrutide has attracted significant interest from the research community investigating metabolic pathways, energy homeostasis, and receptor pharmacology. It is the first peptide of its kind to reach advanced clinical evaluation as a triple incretin agonist, offering researchers a unique tool for studying the interplay between three critical metabolic signaling systems.
The development of Retatrutide builds upon decades of incretin biology research. GLP-1 receptor agonists have been studied extensively since the 1990s for their role in glucose-dependent insulin secretion and appetite regulation. GIP receptor research expanded the field by revealing complementary mechanisms in nutrient sensing and lipid metabolism. The addition of glucagon receptor agonism introduced a third dimension, as glucagon signaling plays a central role in hepatic glucose output, lipolysis, and energy expenditure through thermogenic pathways.
Eli Lilly's Phase 2 clinical trial results, published in the New England Journal of Medicine (NEJM), demonstrated that Retatrutide produced significant and dose-dependent effects in metabolic research endpoints. These findings generated substantial interest in the peptide research community, as the triple-agonist mechanism appeared to engage metabolic pathways that single- or dual-agonist peptides could not fully activate. The trial data provided researchers with a foundation for understanding how simultaneous modulation of three receptor systems may produce synergistic metabolic effects beyond what is achievable with individual receptor targeting.
Retatrutide is a 39-amino-acid synthetic peptide with an approximate molecular weight of 4,500 Da. Its structure has been engineered to bind and activate three distinct G-protein-coupled receptors: GLP-1R, GIPR, and GCGR (glucagon receptor). The peptide incorporates structural modifications that confer balanced activity across all three receptor targets, enabling researchers to study multi-pathway activation in a controlled manner.
The GLP-1 receptor component is associated with glucose-dependent insulin secretion and gastric motility modulation. GIP receptor engagement contributes to nutrient-stimulated insulin release and lipid handling in adipose tissue. Glucagon receptor activation drives hepatic glycogenolysis, gluconeogenesis, and importantly, energy expenditure through increased thermogenesis. The convergence of these three signaling cascades in a single molecule allows researchers to investigate complex metabolic network interactions that would be difficult to study using separate receptor-selective compounds.
Retatrutide is utilized in several key research areas. Metabolic pathway investigation represents the primary application, where researchers study how simultaneous triple-receptor activation modulates glucose homeostasis, insulin dynamics, and energy balance in preclinical models. Lipid metabolism studies examine the peptide's influence on triglyceride handling, free fatty acid cycling, and adipose tissue remodeling when all three receptor systems are engaged concurrently.
Energy expenditure research leverages the glucagon receptor component to investigate thermogenic pathways and basal metabolic rate changes in controlled laboratory settings. Receptor pharmacology studies use Retatrutide to characterize cross-talk between GLP-1, GIP, and glucagon receptor signaling cascades, providing insights into receptor desensitization, downstream second messenger dynamics, and biased agonism. Additionally, comparative studies between Retatrutide and dual-agonist or single-agonist peptides help clarify the incremental contribution of each receptor system to overall metabolic outcomes.
Retatrutide is supplied as a 60mg lyophilized (freeze-dried) powder. For long-term storage, vials should be maintained at -20°C, where the lyophilized peptide remains stable for extended periods. Once reconstituted with bacteriostatic water or sterile saline, the solution should be refrigerated at 2-8°C and used within 30 days. Repeated freeze-thaw cycles should be avoided, as they can compromise peptide integrity and receptor-binding activity. Handle with appropriate laboratory gloves and maintain sterile technique throughout reconstitution to prevent contamination.
This product is sold exclusively for laboratory and scientific research purposes. It is not intended for human or veterinary use, diagnostic purposes, or therapeutic applications. All research must comply with applicable laws and institutional guidelines. By purchasing, you confirm you are a qualified researcher. Please review our full legal disclaimer.